Similarly, studies of glioblastoma, esophageal, breast, and prostate cancers have reported that SOX2 levels increase with increasing tumor grade [14, 29, 33, 39, 40], and for prostate cancer the percentage of SOX2-positive cells correlates with Gleason score [41]. This evidence concerns the gene SOX2 and prostate carcinoma.